The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Updated results of NSABP C-10 with definitive survival analysis.
Laurence E. McCahill
No relevant relationships to disclose
Greg Yothers
Consultant or Advisory Role - Genentech (U)
Saima Sharif
No relevant relationships to disclose
Nicholas J. Petrelli
No relevant relationships to disclose
Samia H. Lopa
No relevant relationships to disclose
Michael J. O'Connell
No relevant relationships to disclose
Norman Wolmark
Consultant or Advisory Role - Sanofi (U)